The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.

Tomoyasu OdaMarino SatohKan NagasawaAtsumi SasakiYutaka HasegawaNoriko TakebeYasushi Ishigaki

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)

Imeglimin clearly shifted the daily glucose profile into an appropriate range in Japanese T2D patients, indicating improvement of short-term glycemic control. Imeglimin is thought to be a promising therapeutic agent for T2D patients, especially those with a low insulin secretory capacity, which is a common phenotype in East-Asian subjects with glucose intolerance.

Keyphrases

glycemic control
type diabetes
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
blood glucose
prognostic factors
peritoneal dialysis
physical activity
patient reported outcomes
adipose tissue
insulin resistance
skeletal muscle
metabolic syndrome